Documentos de Académico
Documentos de Profesional
Documentos de Cultura
ABSORCIÓN
(Biodisponibilidad)
Características de la
molécula (ATB): Tamaño,
Órganos con baja
peso, lipoficidad, Pk,
concentración de ATB
ionización, solubilidad
METABOLISMO DE
PRIMER PASO (vía oral)
Tiempo de vida
media
EXCRECIÓN
(Aclaramiento renal)
Variabilidad Variabilidad
Farmacocinética Farmacodinámica
Variación de 10 a 40%
- Obesidad
Recomendaciones para la dosificación de fármacos en la obesidad mórbida Guillermo Serra Soler, Olga Delgado Sánchez, Iciar
Martínez-López y Olatz Pérez-Rodríguez Med Clin (Barc). España.
Yanneth Moya. EVALUACIÓN DE LA FUNCIÓN RENAL: EL CONCEPTO DE CLEARANCE RENAL Y SU APLICACIÓN DIAGNÓSTICA. Rev. Farmacol.
Chile (2015) 8(3) 25-34
M. F. Waineo BS.The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion .Journal of
Clinical Pharmacy and Therapeutics, 2015, 40, 259–265
Jing-Jing Hao. Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis
.International Journal of Antimicrobial Agents 47 (2016) 28–35
Men P, Li H-B, Zhai S-D, Zhao R-S (2016) Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness:
A Systematic Review and Meta-Analysis. PLoS ONE 11 (1): e0146224. doi:10.1371/journal.pone.0146224
Van Herendael et al. Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin? . Annals of
Intensive Care 2012, 2:22
http://www.vancomycin-calculator.com/
N. P. Fewel. Comparison of open-access vancomycin dosing websites. J Clin Pharm Ther. 2017 Apr;42(2):128-131. doi:
10.1111/jcpt.12466. Epub 2016 Oct 18
Page Crew. Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis
Am J Health-Syst Pharm. 2015; 72:1856-64
M. Bassetti. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus
aureus after more than 10 years of experience with linezolid Clin Microbiol Infect 2014; 20 (Suppl. 4): 3–18
Tsoulas C. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?. Int J
Antimicrob Agents. 2015 Jul;46(1):1-7.
H Å KAN HANBERGER. Rational use of aminoglycosides — Review and recommendations by the Swedish Reference Group for Antibiotics (SRGA).
Scandinavian Journal of Infectious Diseases, 2013; 45: 161–175
Tambyah PA, Hara GL, Daikos GL, et al. Treatment of extensively drug-resistant Gram-negative infections in critically ill patients:
Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012. J Glob
Antimicrob Resist 2013;1(3):117-22.
David D. Khan. A pharmacokinetic–pharmacodynamic (PKPD) model based on in vitro time–kill data predicts the in vivo PK/PD index of
colistin. Journal of Antimicrobial Chemotherapy Advance Access published March 16, 2016
Vancomicina Nefrotoxicidad
Aminoglucosidos Nefro, ototoxicidad y neurotoxicidad
Colistina Nefro y neurotoxicidad
Rifampicina inductor enzimático del CYP 3A4
Antituberculosos hepatotoxicidad
El genotipo NAT2 lento y GSTM1 tienen un efecto modesto sobre susceptibilidad genética a injuria
hepática asociada a drogas antituberculosas.
Cai Y, Yi J, Zhou C, Shen X (2012) Pharmacogenetic Study of Drug-Metabolising Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver
Injury: A Meta-Analysis. PLoS ONE 7(10): e47769. doi:10.1371/journal.pone.0047769
Diagnóstico de infección
Paciente inmunocompetente o
inmunosuprimido
Tipo de paciente
www.estudiosmyc.com